US drug major Eli Lilly has been granted a temporary restraining order preventing the launch of a generic version of Evista (raloxifene) by Israel's Teva Pharmaceutical Industries. The latter had previously stated that it was prepared to launch the copy-drug before pending patent litigation being heard by the US District Court for the Southern District of Indiana regarding the product had been completed. Lilly maintains that Teva's challenge to its patent is without merit and says it expects to prevail in the litigation.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze